ResMed reported $5.65B of revenue over the trailing twelve months, +9.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $5.65B (to Q4 2026). Net income: $1.52B, trailing twelve months to Q4 2026. Free cash flow: $1.65B, trailing twelve months to Q4 2026. Operating margin: 33%, trailing twelve months to Q4 2026.

RMDResMed

Healthcare

$230.03-15% 1Y

$230.03

$182.8252 weeks$281.12

Latest close: back above its 200-day averageOct 9, 2026what changed →

RMD as reported

ResMed reported $5.65B of revenue over the trailing twelve months, +9.9% on the year before. 11 reported series are charted on this page, each one as filed.

$5.65B

Revenue, trailing twelve months · to Q4 2026 · +9.9% against the twelve months before

Net income: $1.52B
Net income · +8.8% year on year · trailing twelve months to Q4 2026
Free cash flow: $1.65B
Free cash flow · −0.73% year on year · trailing twelve months to Q4 2026
Operating margin: 33%
Operating margin · trailing twelve months to Q4 2026

Details›

Every series Ryufin has for RMD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$5.65B	+9.9%	Q4 2026
Net income	$1.52B	+8.8%	Q4 2026
EPS	$10.43	+9.7%	Q4 2026
Gross margin	61%	n/a	Q4 2026
Operating margin	33%	n/a	Q4 2026
Net margin	27%	n/a	Q4 2026
ROE	23%	n/a	Q4 2026
ROA	17%	n/a	Q4 2026
ROIC	26%	n/a	Q4 2026
Free cash flow	$1.65B	−0.73%	Q4 2026
P/E	22.1	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.